Immunovant, Inc. Common Stock (IMVT) is a publicly traded Healthcare sector company. As of May 20, 2026, IMVT trades at $32.94 with a market cap of $5.40B and a P/E ratio of -9.53. IMVT moved +22.56% today. Year to date, IMVT is +1.47%; over the trailing twelve months it is +78.84%. Its 52-week range spans $12.72 to $32.10. Analyst consensus is strong buy with an average price target of $44.88. Rallies surfaces IMVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
8 analysts cover IMVT: 0 strong buy, 6 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $44.88.
| Metric | Value |
|---|---|
| Price | $32.94 |
| Market Cap | $5.40B |
| P/E Ratio | -9.53 |
| EPS | $-2.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $32.10 |
| 52-Week Low | $12.72 |
| Volume | 4.12M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-413.84M |
| Gross Margin | 0.00% |
8 analysts cover IMVT: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.88.